EMA/480376/2023

European Medicines Agency decision

P/0449/2023

of 27 October 2023

on the acceptance of a modification of an agreed paediatric investigation plan for blinatumomab (Blincyto), (EMEA-000574-PIP02-12-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0449/2023

of 27 October 2023

on the acceptance of a modification of an agreed paediatric investigation plan for blinatumomab (Blincyto), (EMEA-000574-PIP02-12-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0145/2014 issued on 13 June 2014, the decision P/0014/2016 issued on 29 January 2016, the decision P/0401/2017 issued on 19 December 2017, and the decision P/0143/2020 issued on 18 April 2020,

Having regard to the application submitted by Amgen Europe B.V. on 3 July 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 October 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for blinatumomab (Blincyto), powder for solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Amgen Europe B.V., Minervum 7061, 4817 ZK – Breda, The Netherlands.

EMA/PDCO/322749/2023
Amsterdam, 13 October 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000574-PIP02-12-M04

Scope of the application

Active substance(s):

Blinatumomab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of acute lymphoblastic leukaemia

Pharmaceutical form(s):

Powder for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Amgen Europe B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Amgen Europe B.V. submitted to the European Medicines Agency on 3 July 2023 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0145/2014 issued on 13 June 2014, the decision P/0014/2016 issued on 29 January 2016, the decision P/0401/2017 issued on 19 December 2017, and the decision P/0143/2020 issued on 18 April 2020.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 14 August 2023.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of acute lymphoblastic leukaemia.

The waiver applies to:

- preterm newborn infants and term newborn infants (from birth to less than 28 days of age);
- powder for solution for infusion; intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition

Treatment of acute lymphoblastic leukaemia.

2.1.1. Indication(s) targeted by the PIP

Treatment of children with previously untreated high-risk first relapse of B precursor acute lymphoblastic leukaemia.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 month to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for solution for infusion.

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable.
Non-clinical studies	Not applicable.
Clinical studies	**Study 1** Multi-centre, open-label, multiple-dose, dose-escalation trial to evaluate pharmacokinetics, pharmacodynamics, toxicity, safety and anti-tumour activity of blinatumomab in children from birth to less than 18 years of age with a relapse of B precursor acute lymphoblastic leukaemia involving the bone marrow or a refractory acute lymphoblastic leukaemia and for whom no effective treatment is known, with an extension phase.

	Study 2 Randomised, controlled, open-label trial to evaluate the pharmacokinetics, safety and efficacy of blinatumomab compared to multi-agent consolidation chemotherapy in children from 1 month to less than 18 years of age with a first, high-risk relapse of B-precursor acute lymphoblastic leukaemia.
Extrapolation, modelling & simulation studies	**Study 3** Pharmacokinetic-pharmacodynamic analysis to inform the dose for study 2.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues and efficacy in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of acute lymphoblastic leukaemia

Authorised indication(s):

- Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.
- Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
- Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation.
- Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy.

Authorised pharmaceutical form(s):

Powder for solution for infusion

Authorised route(s) of administration:

Intravenous use.